Unusual Presentations of Melanoma. Melanoma of Unknown Primary Site, Melanoma Arising in Childhood, and Melanoma Arising in the Eye and on Mucosal Surfaces

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 1059-1073

  Sondak, Vernon K ^a,b   Messina, Jane L ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adjuvant therapy; Immunotherapy; Melanoma; Mucosal melanoma; Pediatric melanoma; Targeted therapy; Unknown primary; Uveal melanoma

Indexed keywords

INTERFERON;

CANCER ADJUVANT THERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CHILDHOOD CANCER; CHOROID MELANOMA; CUTANEOUS MELANOMA; DERMIS; FOLLOW UP; GENETIC DIFFERENCE; HUMAN; IMMUNE RESPONSE; LYMPHATIC DRAINAGE; MELANOCYTE; MELANOMA; METASTASIS; PHYSICAL EXAMINATION; REVIEW; SUBCUTANEOUS TISSUE; ADJUVANT THERAPY; ADOLESCENT; ANAMNESIS; CHILD; EYE TUMOR; IMMUNOTHERAPY; INFANT; LYMPH NODE METASTASIS; METHODOLOGY; MUCOSA; MUCOSAL MELANOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PEDIATRIC MELANOMA; PRESCHOOL CHILD; SKIN TUMOR; TARGETED THERAPY; UVEA MELANOMA; VISCERA;

ADJUVANT THERAPY; IMMUNOTHERAPY; MELANOMA; MUCOSAL MELANOMA; PEDIATRIC MELANOMA; TARGETED THERAPY; UNKNOWN PRIMARY; UVEAL MELANOMA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DERMIS; EYE NEOPLASMS; HUMANS; INFANT; LYMPHATIC METASTASIS; MEDICAL HISTORY TAKING; MELANOMA; MUCOUS MEMBRANE; NEOPLASMS, UNKNOWN PRIMARY; PHYSICAL EXAMINATION; SKIN NEOPLASMS; VISCERA;

EID: 84907671227     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.010     Document Type: Review

References (73)

1. Chang A.E., Hynds Karnell L., Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. A summary of 84,836 cases from the past decade. Cancer 1998, 83:1664-1678.
2. Wong J.R., Harris J.K., Rodriguez-Galindo C., et al. Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics 2013, 131:846-854.
3. Cormier J.N., Xing Y., Feng L., et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006, 106:2012-2020.
4. Lee C.C., Faries M.B., Wanek L., et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. JClin Oncol 2008, 26:535-541.
5. Egberts F., Bergner I., Krüger S., et al. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol 2014, 25:246-250.
6. Sondak V.K., Tuthill R., Moon J., et al. Should unknown primary melanomas be excluded from adjuvant trials? Insights from SWOG S0008. JClin Oncol 2010, 28:15S. (Suppl I):615s.
7. Weide B., Faller C., Elsässer M., et al. Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour. PLoS One 2013, 8:e66953.
8. Kirkwood J.M., Manola J., Ibrahim J., et al. Apooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
9. Eggermont A.M., Suciu S., Testori A., et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. JClin Oncol 2012, 30:3810-3818.
10. Mocellin S., Lens M.B., Pasquali S., et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013, (6). CD008955.
11. Burmeister B.H., Henderson M.A., Ainslie J., et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012, 13:589-597.
12. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
13. McArthur G.A., Chapman P.A., Robert C., et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
14. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. NEngl J Med 2012, 367:1694-1703.
15. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. NEngl J Med 2013, 369:134-144.
16. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. NEngl J Med 2013, 369:122-133.
17. Swetter S.M., Ecker P.M., Johnson D.L., et al. Primary dermal melanoma. A distinct subtype of melanoma. Arch Dermatol 2004, 140:99-103.
18. Balch C.M., Gershenwald J.E., Soong S.-J., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27:6199-6206.
19. Cassarino D.S., Cabral E.S., Kartha R.V., et al. Primary dermal melanoma: distinct immunohistochemical findings and clinical outcome compared with nodular and metastatic melanoma. Arch Dermatol 2008, 144:49-56.
20. Lyle P.L., Amato C.M., Fitzpatrick J.E., et al. Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma. Am J Surg Pathol 2008, 32:858-866.
21. Lee C.C., Faries M.B., Wanek L., et al. Improved survival for stage IV melanoma from an unknown primary site. JClin Oncol 2009, 27:3489-3495.
22. Council on Environmental Health Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011, 127:588-597.
23. Balk S.J., Fisher D.E., Geller A.C. Teens and indoor tanning: a cancer prevention opportunity for pediatricians. Pediatrics 2013, 131:772-785.
24. Gerami P., Busam K., Cochran A., et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical Spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol 2014, 38:934-940.
25. Reed D., Kudchadkar R., Zager J.S., et al. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. JNatl Compr Canc Netw 2013, 11:679-686.
26. Livestro D.P., Kaine E.M., Michaelson J.S., et al. Melanoma in the young: differences and similarities with adult melanoma. A case-matched controlled analysis. Cancer 2007, 110:614-624.
27. Coit D.G., Ernstoff M.S., Busam K.J. Is pediatric melanoma always malignant?. Cancer 2013, 119:3910-3913.
28. Lange J.R., Palis B.E., Chang D.C., et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. JClin Oncol 2007, 25:1363-1368.
29. Han D., Zager J.S., Han G., et al. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 2012, 19:3888-3895.
30. Averbook B.J., Lee S.J., Delman K.A., et al. Pediatric melanoma: analysis of an international registry. Cancer 2013, 119:4912-4919.
31. Cordero K.M., Gupta D., Frieden I.J., et al. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. JAm Acad Dermatol 2013, 68:913-925.
32. Pearce M.S., Salotti J.A., Little M.P., et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumors: a retrospective cohort study. Lancet 2012, 380:499-505.
33. Berg P., Wennberg A.M., Tuominen R., et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 2004, 14:251-255.
34. Daniotti M., Ferrari A., Fregerio S., et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. JInvest Dermatol 2009, 129:1759-1768.
35. Gerami P., Zembowicz A. Update on fluorescence in situ hybridization in melanoma: state of the art. Arch Pathol Lab Med 2011, 135:830-837.
36. Gerami P., Cooper C., Bajaj S., et al. Outcomes of atypical Spitz tumors with chromosomal copy numbers aberrations and conventional melanomas in children. Am J Surg Pathol 2013, 37:1387-1394.
37. Conway C., Beswick S., Elliott F., et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 2010, 49:425-438.
38. Gerami P., Scolyer R.A., Xu X., et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol 2013, 37:676-684.
39. Ludgate M.W., Fullen D.R., Lee J., et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer 2009, 115:631-641.
40. Mills O.L., Marzban S., Zager J.S., et al. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. JCutan Pathol 2012, 39:331-336.
41. Kirkwood J.M., Jukic D.M., Averbook B.J., et al. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol 2009, 36:419-431.
42. Cao M.M., Schwartz J.L., Wechsler D.S., et al. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer 2004, 43:1-8.
43. Navid F., Furman W.L., Fleming M., et al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer 2005, 103:780-787.
44. Daud A.I., Xu C., Hwu W.J., et al. Pharmacokinetic/pharmacodynamics analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2010, 67:657-666.
45. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. JClin Oncol 2006, 24:4340-4346.
46. Koomen E.R., de Vries E., van Kempen L.C., et al. Epidemiology of extracutaneous melanoma in the Netherlands. Cancer Epidemiol Biomarkers Prev 2010, 19:1453-1459.
47. Bastian B.C., Esteve-Puig R. Targeting activated KIT signaling for melanoma therapy. JClin Oncol 2013, 31:3288-3290.
48. Minor D.R., Kashani-Sabet M., Garrido M., et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 2012, 18:1457-1463.
49. Aulmann S., Sinn H.P., Penzel R., et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol 2014, [Epub ahead of print].
50. Yeh J.J., Shia J., Hwu W.J., et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg 2006, 244:1012-1017.
51. Iddings D.M., Fleisig A.J., Chen S.L., et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?. Ann Surg Oncol 2010, 17:40-44.
52. Sugiyama V.E., Chan J.K., Kapp D.S. Management of melanomas of the female genital tract. Curr Opin Oncol 2008, 20:565-569.
53. Kobayashi K., Ramirez P.T., Kim E.E., et al. Sentinel node mapping in vulvovaginal melanoma using SPECT/CT lymphoscintigraphy. Clin Nucl Med 2009, 34:859-861.
54. Christopherson K., Malyapa R.S., Werning J.W., et al. Radiation therapy for mucosal melanoma of the head and neck. Am J Clin Oncol 2013, [Epub ahead of print].
55. Bishop K.D., Olszewski A.J. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer 2014, 134:2961-2971.
56. Lian B., Si L., Cui C., et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013, 19:4488-4498.
57. Griewank K.G., Westekemper H., Murali R., et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013, 19:3143-3152.
58. Hu D., McCormick S.A. Progress in the studies of etiology, epidemiology and pathogenesis of ocular melanomas. Eye Sci 2011, 26:18-22.
59. Shields C.L. The hunt for the secrets of uveal melanoma. Clin Experiment Ophthalmol 2008, 36:277-280.
60. Van Raamsdonk C.D., Bezrookove V., Green G., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
61. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. NEngl J Med 2010, 363:2191-2199.
62. Harbour J.W., Onken M.D., Roberson E.D., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
63. Shields C.L., Ganguly A., Bianciotto C.G., et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011, 118:396-401.
64. Onken M.D., Worley L.A., Char D.H., et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012, 119:1596-1603.
65. Weber J.L., Smalley K.S., Sondak V.K., et al. Conjunctival melanomas harbor BRAF and NRAS mutations-letter. Clin Cancer Res 2013, 19:6329-6330.
66. Njauw C.N., Kim I., Piris A., et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012, 7:e35295.
67. Busam K.J., Wanna M., Wisener T. Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression. A clue to a hereditary tumor syndrome. JAMA Dermatol 2013, 49:335-339.
68. Murray T.G., Markoe A.M., Gold A.S., et al. Long-term followup comparing two treatment dosing strategies of (125)I plaque radiotherapy in the management of small/medium posterior uveal melanoma. JOphthalmol 2013, 2013:517032.
69. Cohen V.M., Tsimpida M., Hungerford J.L., et al. Prospective study of sentinel lymph node biopsy for conjunctival melanoma. Br J Ophthalmol 2013, 97:1525-1529.
70. Lane A.M., Egan K.M., Harmon D., et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009, 116:2206-2212.
71. Ryu S.W., Saw R., Scolyer R.A., et al. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. JSurg Oncol 2013, 108:129-135.
72. Forster M.R., Rashid O.M., Perez M.C., et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. JSurg Oncol 2014, 109:434-439.
73. Agarwala S.S., Eggermont A.M., O'Day S., et al. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014, 120:781-789.